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MicroRNAs (miRNAs) and siRNAs have enormous potential as
cancer therapeutics, but their effective delivery to most solid
tumors has been difficult. Here, we show that a new lung-target-
ing nanoparticle is capable of delivering miRNA mimics and siRNAs
to lung adenocarcinoma cells in vitro and to tumors in a genetically
engineered mouse model of lung cancer based on activation of
oncogenic Kirsten rat sarcoma viral oncogene homolog (Kras)
and loss of p53 function. Therapeutic delivery of miR-34a, a p53-
regulated tumor suppressor miRNA, restored miR-34a levels in
lung tumors, specifically down-regulated miR-34a target genes,
and slowed tumor growth. The delivery of siRNAs targeting Kras
reduced Kras gene expression and MAPK signaling, increased ap-
optosis, and inhibited tumor growth. The combination of miR-34a
and siRNA targeting Kras improved therapeutic responses over
those observed with either small RNA alone, leading to tumor
regression. Furthermore, nanoparticle-mediated small RNA de-
livery plus conventional, cisplatin-based chemotherapy prolonged
survival in this model compared with chemotherapy alone. These
findings demonstrate that RNA combination therapy is possible in
an autochthonous model of lung cancer and provide preclinical
support for the use of small RNA therapies in patients who
have cancer.
miR-34 | nanotechnology
MicroRNAs (miRNAs) mediate multiple biological pro-cesses, and alterations in miRNA function have been as-
sociated with different diseases, including cancer (1–4). In model
systems, the overexpression of tumor suppressor miRNAs or
inhibition of oncogenic miRNAs has shown therapeutic potential
(5). Moreover, siRNAs hold great promise as therapeutic agents
for cancer through RNAi of oncogene expression (6–9). Al-
though numerous studies have evaluated small RNA therapy
mediated by delivery vehicles in xenograft models of cancer (5, 6,
9, 10), the relevance of these results is limited by the fact that
tumors are implanted in ectopic sites. Similarly, although viral-
mediated small RNA delivery has led to promising antitumor
responses in genetically engineered mouse models of cancer (11,
12), the utility of viral delivery systems may be limited by pre-
existing immunity, toxicity, concerns about mutational genomic
insertions, and insufficient delivery efficiency. To overcome
these barriers, many nonviral small RNA delivery vehicles have
been designed (13). Although most of these delivery vehicles
have been tested in xenograft models (14, 15), some have been
evaluated in autochthonous mouse models as well (16, 17).
Lung cancer is an attractive cancer type for local or systemic
small RNA delivery treatment (7). It is the leading cause of
cancer death worldwide, with non-small cell lung cancers
(NSCLCs) accounting for 85% of all lung cancer cases (18). The
most common NSCLC subtype, adenocarcinoma, is associated
with frequent mutations in KRAS (∼20–30%) and TP53 (∼50%)
(18). Targeted mutations of these two genes in the adult murine
lung epithelium results in lung adenocarcinomas that mimic the
histopathological progression of the human disease (19). The so-
called “KP”model of lung adenocarcinoma involves activation of
an oncogenic Kras allele (KrasG12D) and inactivation of two
conditional (floxed) alleles of p53 following intranasal or intra-
tracheal administration of recombinant virus particles expressing
Cre recombinase (19). Although lung cancers in the KP model
respond to certain chemotherapeutics, durable responses have
not been observed (20–25). Of note, despite recent progress
in the treatment of human lung cancer carrying activating
mutations in EGFR and translocations involving ALK with
targeted anticancer agents (18, 26), advanced KRAS-mutant
lung cancers are treated with conventional therapy, most often
with limited success.
Because lung adenocarcinoma is so often associated with
mutations in KRAS and TP53, targeted inhibition of KRAS ex-
pression and stimulation of TP53 effector functions are attractive
therapeutic strategies for this disease. However, direct and spe-
cific KRAS inhibition by small-molecule compounds has been
elusive (26, 27). As a result, KRAS is a promising candidate for
RNAi-based therapy, which can inhibit traditionally undruggable
targets by directly reducing mRNA expression. Importantly,
mouse models using conditional expression of oncogenic Ras
alleles have demonstrated that withdrawal of RAS signaling
results in rapid tumor regression in established tumors (28–
30). These data provide proof of principle that oncogenic
RAS can play a critical role in tumor maintenance and suggest
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that inhibiting oncogenic RAS with siRNA might be an
effective therapy.
The p53 tumor suppressor gene (also known as TP53 or Trp53)
is among the most frequently mutated genes in human cancer
(31, 32); multiple tumor types exhibit a high frequency of mu-
tation or loss of this key tumor suppressor. Restoring p53 func-
tion induces antitumor effects in multiple tumor types (reviewed
in ref. 32), including lung cancer (31, 33). Despite its high fre-
quency of involvement in human cancer, loss-of-function muta-
tions in p53 are a challenging therapeutic target, with the
possible exception of drugs that convert mutant p53 proteins to
a functional state (32). The miR-34 family of miRNAs comprises
direct transcriptional targets of p53 and can mediate certain
effects of the p53 response (34, 35). The three members of this
family, miR-34a, miR-34b, and miR-34c, have been shown to
inhibit genes involved in controlling cell cycle progression, me-
tabolism, and apoptosis (36–38). miR-34 overexpression has
been shown to limit cancer cell growth and tumor progression in
subcutaneous models and an autochthonous model of NSCLC,
in which oncogenic Kras is activated without the concurrent
deletion of p53 (12, 17, 35, 39). These data suggest that sys-
tematic delivery of miR-34 might be an effective strategy to
stimulate the tumor suppressor pathway downstream of p53.
Although the therapeutic potential of RNA therapies is sub-
stantial, the biggest challenge in small RNA therapy remains the
efficient and specific delivery to the desired target tissues (7). In
vivo RNA delivery is limited by several factors, including re-
ticuloendothelial system clearance and nuclease degradation.
Nanomaterials formed with gold, silver, protein, cholesterol,
DNA origami, lipids, and cationic polymers have all been in-
vestigated as potential vehicles for small RNA delivery in vivo
(40). However, despite the diverse chemical and physical struc-
tures examined to date, highly efficient nonviral delivery has
been largely limited to hepatocytes. For example, lipids and
lipid-like materials, termed lipidoids, have reduced hepatocyte
target gene expression at doses as low as 0.01 mg/kg (41, 42).
Small RNA cancer therapies are beginning to be tested in
human clinical trials. Lipid nanoparticles carrying VEGF and
kinesin spindle protein siRNA have been tested in phase I
clinical trials in patients who have cancer with liver metastasis
(43), and cyclodextrin polymer-based nanoparticles carrying ri-
bonucleotide reductase M2 siRNA have been tested in patients
with solid tumors (44). These studies have shown promising
pharmacodynamics and tolerability, indicating that nanoparticle-
mediated siRNA delivery may be effective in patients. However,
to extend small RNA therapy to other major cancer types, in-
cluding lung cancer, delivery vehicles that target nonliver tissues
are urgently needed.
Recently, we reported a new class of nanoparticle-forming
compounds that were generated by combinatorial chemical
synthesis (45). The compounds were synthesized by conjugating
epoxide-terminated lipids to low-molecular weight polyamines
with an epoxide ring-opening reaction. The resulting structures
were tested for their ability to complex siRNA and reduce gene
expression in vitro; the most effective candidates were then
tested in vivo. We identified one compound from a library of
over 500 candidate delivery materials that delivered siRNA to
lung endothelium in vivo, silencing target genes in pulmonary
vasculature at doses several hundred-fold lower than previously
reported vehicles. This compound, named 7C1, preferentially
targeted lung vasculature without significantly transfecting im-
mune cells or hepatocytes at low doses (45). These observations
suggested that 7C1 might also deliver therapeutic RNA to lung
cancer cells, at higher doses. Here, we describe the treatment of
KP lung tumors by systemic delivery of a miR-34 mimic and
siRNAs targeting Kras using 7C1 nanoparticles. Delivery of ei-
ther one of these small RNAs modulated biological function in
tumors and elicited antitumor effects. The concurrent delivery of
both caused measurable regression of established tumors and
prolonged survival of chemotherapy-treated mice. These results
demonstrate that effective delivery of therapeutic small RNAs is
possible in an autochthonous solid tumor model in the mouse and
provide further impetus to develop small RNA-based treatment
strategies for human patients with lung cancer.
Results
Delivery of siRNA to Lung Adenocarcinoma Cells in Vitro. The 7C1
compound was discovered using a combinatorial chemical engi-
neering approach followed by cell-based and whole-animal
screening (45). The 7C1 compound was synthesized by reacting
600 molecular-weight polyethyleneimine with a 15-carbon lipid
tail in ethanol for 48–72 h. This chemical reaction generated
a compound that, when mixed with C14PEG2000 at a 7C1/ PEG
molar ratio equal to 80:20, formed nanoparticles with a multi-
lamellar structure, a diameter of 50 nm, and a zeta potential
equal to zero at physiological pH (Fig. 1A).
Because 7C1 allows for delivery of siRNA to pulmonary en-
dothelial cells in vivo, we examined whether it could deliver
small RNAs to lung tumor cell lines and lung tumors. We first
tested 7C1-mediated siRNA delivery to KP-derived lung ade-
nocarcinoma lines (KP cells) in vitro using fluorescence and
confocal microscopy. The 7C1 nanoparticles complexed with
Cy5.5 fluorophore-labeled siRNA substantially increased the
intracellular Cy5.5 signal in KP cells (Fig. 1B). Using KP cells
stably expressing firefly luciferase, we observed that 7C1 nano-
particles carrying siRNA targeting luciferase (siLuc) also reduced
luminescence in a dose-dependent fashion, whereas nanoparticles
carrying small interfering GFP (siGFP) had no effect (Fig. 1 C
and D). Conversely, in KP cells stably expressing GFP, 7C1
nanoparticles carrying Cy5.5-siGFP simultaneously reduced
GFP expression and increased Cy5.5 fluorescence (Fig. S1).
Taken together, these data demonstrate 7C1 nanoparticles can
deliver siRNA in cultured murine lung cancer cells.
Delivery of siRNA to Lung Adenocarcinomas in Vivo. Previous anal-
ysis has demonstrated that 7C1 is well tolerated in mice and does
not induce liver enzymes (45). To assess the ability of 7C1
nanoparticles to deliver small RNAs in lung adenocarcinomas in
vivo, KP mice were crossed with two strains carrying Lox-STOP-
Lox reporter alleles, R26LSL-tdTomato and R26LSL-Luciferase (46, 47), to
generate KrasLSL-G12D/wt;p53flox/flox;R26LSL-Luciferase/LSL-tdTomatomice.
In this model, intranasal inhalation of Adeno-Cre causes deletion
of p53 and activation of KrasG12D, as well as the reporters luciferase
and tdTomato, in developing lung tumors (Fig. S2A). Ten weeks
after tumor initiation, mice were i.v. injected with a single 1.5-mg/kg
dose of 7C1 nanoparticles formulated with Cy5.5-siLuc. Animals
were killed at different time points, and lung tissue was isolated
for confocal image analysis. To measure the luciferase signal at
the single cell level, we performed immunofluorescent staining
on lung tumor sections using a luciferase antibody. Tumor lu-
ciferase staining diminished 24 h after dosing, whereas tdTomato
fluorescence remained constant over time, indicating that
siLuc selectively silenced gene expression in tumors in vivo
following i.v. injection (Fig. 1E and Fig. S2B). The 7C1 carrying
siLuc also transiently reduced the luciferase signal in the lung
by whole-body luciferase imaging (Fig. S2C). Biodistribution
studies confirmed siRNA delivery to KP tumors in vivo; lung
tumors isolated from mice injected with Cy5.5-labeled siRNA
showed Cy5.5 fluorescence (n = 3 mice per group; Fig. S3). Cy5.5
signal was also distributed to kidneys and other organs (Fig. S3).
Systemic miR-34a Delivery Delays Lung Tumor Progression. We next
examined whether miRNA delivery might cause therapeutic
responses by restoring an effector arm of the p53 pathway to
these p53-deficient tumors. As predicted by the known regulation
of the miR-34 family by p53, RT-quantitative (Q)-PCR analysis
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showed that mature miR-34a and miR-34c were relatively
underexpressed in isolated KP lung tumors compared with nor-
mal lung samples (Fig. S4). A 22-nt dsRNA, 2-O-methyl, mod-
ified to reduce immunostimulation and nuclease degradation,
with the mature miR-34a antisense strand sequence and a com-
plementary sense strand was used as the miR-34a mimic (48, 49)
(Fig. S5A). Groups of three KP mice with established lung
tumors were injected i.v. with a single 1.5-mg/kg dose of 7C1
nanoparticles complexed with siLuc, which served as a control
siRNA, or the miR-34a mimic (Fig. 2A). Lung tumors were
isolated 48 h and 68 h following injection, and miR-34a and miR-
34c mature miRNAs were measured by RT-Q-PCR probes rec-
ognizing both endogenous miR-34 as well as the miRNA mimic.
miR-34a increased in tumors isolated from miR-34a–treated
animals compared with tumors isolated from mice treated with
siLuc, whereas miR-34c levels remained constant (Fig. 2B).
Importantly, miR-34a treatment reduced the mRNA expression
of Ccnd1, Sirt1, Cdk6, and Ccne2 (34), demonstrating that de-
livery of miR-34a achieved functional inhibition of canonical
miR-34a targets in vivo (Fig. 2C). To optimize nanoparticle
administration, groups of four KP mice were injected with the
miR-34a nanoparticle formulation i.v., intranasally, or i.p. (Fig.
S5B). The i.v. injection increased miR-34a levels in lung tumors
the most, resulting in a 27-fold increase relative to mice treated
with siLuc (Fig. S5C).
We next investigated the effects of miR-34a delivery on lung
tumor development. Ten weeks after infection with Adeno-Cre,
KP mice were scanned by microcomputed tomography (microCT)
to measure individual tumor volumes. Tumor-bearing KP mice
were i.v. injected with PBS, nanoparticles carrying siLuc, or
nanoparticles carrying miR-34a at a dose of 1.5 mg/kg twice each
week for 4 wk (n = 6 mice per group). miR-34a treatment sig-
nificantly delayed tumor progression compared with siLuc and
PBS control animals, which grew rapidly over this time period
(Fig. 2D). To explore the mechanism of miR-34a in tumor
suppression, lung tumors were harvested 72 h after a single i.v.
injection of 1.5 mg/kg of miR-34a. Consistent with the function
of miR-34a in inducing cell cycle arrest (34, 35), tumors treated
with miR-34a showed reduced levels of proliferation as mea-
sured by Ki67 or phospho-histone H3 staining compared with
PBS- or siLuc-treated mice (Fig. 2 E and F). Cleaved caspase
3 (CC3) staining, a marker for apoptosis, did not significantly
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Fig. 1. Efficient delivery of siRNAs to murine lung
adenocarcinoma in vitro and in vivo. (A) 7C1-siRNA
particle diameter, weighted by volume. (B) Cy5.5
fluorescence in KP (KrasLSL-G12D/wt;p53flox/flox) cells
following incubation with 7C1 nanoparticles for-
mulated with Cy5.5-labeled siRNA at an siRNA
concentration of 30 nM. Cells were washed exten-
sively and imaged using an epifluorescence or con-
focal microscope, 200× and 1600× magnification,
respectively. Nuclei were stained with DAPI (blue).
(C) Firefly luminescence in KP cells following in-
cubation with 7C1 nanoparticles carrying siLuc or
siGFP (with the latter acting as a control). Repre-
sentative images are shown. The color bar denotes
luciferase signal intensity. (D) Quantification of
luciferase signal in C. Error bars are SD (n = 3 wells).
(E) 7C1 nanoparticles carrying siLuc knockdown lu-
ciferase expression in KP tumors in vivo. Lung
tumors were initiated in KrasLSL-G12D/wt;p53flox/flox;
R26LSL-Luciferase/LSL-tdTomato mice with Adeno-Cre. Ten
weeks later, mice were dosed with 1.5 mg/kg of
Cy5.5-siLuc formulated with 7C1, and lung tumors
were harvested for luciferase immunostaining and
determination of natural fluorescence of Tomato
and Cy5.5. (Magnification: 400× confocal images.)
Shown are representative images from seven or
more tumors analyzed per time point.
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increase between the three groups (Fig. 2F). Despite the fact that
miR-34a was increased in normal lung tissue in these animals as
well (Fig. S5B), animals treated with miR-34a showed negligible
weight loss over the treatment period (Fig. S6A). These results
provide compelling evidence that delivery of exogenous miR-34a
can suppress lung tumor development in an aggressively growing
autochthonous solid tumor model.
Systemic Small Interfering Kras Delivery Elicited Anti-Lung Tumor
Effects. In addition to lacking p53 function, the tumors in KP
mice carry an activated Kras oncogene, and oncogenic Kras is an
attractive target for small RNA therapy. We screened nine
siRNAs (2-O-methyl–modified) for efficient knockdown of
mouse Kras in KP cells (Fig. S7A). One siRNA, si923 [hereafter
termed small interfering Kras (siKras)], reduced total Kras
mRNA expression by 87% 48 h after transfection at a 10 nM
concentration compared with siLuc siRNA (Fig. S7A). This
siKras sequence targets the 3′-UTR of Kras mRNA, and there-
fore inhibits both the oncogenic and WT Kras. As shown in Fig.
3A, incubation of KP cells with 7C1 nanoparticles carrying siKras
resulted in a dose-dependent decrease in cell number and re-
duced phospho-Erk (pErk; p42/p44 MAPK) levels, a biomarker
of Kras activity (27). To examine whether these effects were due
to on-target inhibition of Kras, a KrasG12D cDNA was cloned
lacking the 3′-UTR (KrasG12D*), thus rendering it insensitive to
silencing. KP cells expressing the KrasG12D* cDNA maintained
pErk levels and showed no growth defects following exposure to
siKras (Fig. 3B and Fig. S7B).
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Fig. 2. Systemic miR-34a delivery delays lung tu-
mor progression. (A) Experimental design. (B) 7C1
nanoparticles deliver miR-34a mimics to KP lung
tumors. Expression levels of mature miR-34a and
miR-34c in lung tumors was measured by Q-PCR 48 h
and 68 h after a single injection of 1.5 mg/kg of 7C1-
siLuc or 7C1–miR-34a. Error bars are SD (n = 4
tumors per group). (C) Expression levels of miR-34a
target genes in lung tumors measured by Q-PCR.
Error bars are SD (n = 3 tumors per group). Ccnd1,
Sirt1, Cdk6, and Ccne2 are miR-34a target genes. (D)
Relative tumor volume measured by microCT shows
a significant delay in lung tumor progression in KP
mice treated with 7C1–miR-34a compared with 7C1-
siLuc or PBS. Ten weeks after tumor initiation, mice
were dosed with 1.5 mg/kg of siRNA or miRNA
mimic twice weekly. Error bars are SD (n = 6 mice
per group, n = 1 tumor per mouse). (E) Quantifica-
tion of dividing cells marked by Ki67 and phospho-
histone H3 (pHH3) in treated tumors (n = 10 tumors
per group). (F) Representative histology and immu-
nohistochemistry staining of lung tumors from mice
treated with PBS, 7C1-siLuc, or 7C1–miR-34a. (Inset)
Bortezomib-treated KP tumors serve as a positive
control for CC3 staining. (Scale bars: 50 μm.) *P <
0.05; **P < 0.01. siCntrol, small interfering control.
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To test the effects of siKras in vivo, tumor-bearing KP mice
were treated with different doses of 7C1 nanoparticle formulated
with siKras or siLuc (n = 4 mice per group). Following two
injections of 2 mg/kg, siKras treatment reduced Kras mRNA in
isolated tumors by 63% compared with tumors treated with siLuc
(Fig. 3C). To monitor lung tumor progression following siKras
treatment, we initiated lung tumors in a cohort of KP mice. Ten
weeks later, groups of six mice were injected i.v. with nano-
particles carrying 1.5 mg/kg of siKras or siLuc every other day for
four doses. Individual lung tumor volumes were measured by
microCT imaging over a 2.5-wk period. As shown in Fig. 3D,
siKras-treated tumor growth was significantly inhibited com-
pared with tumors treated with siLuc. Moreover, a modest re-
gression was observed in some tumors (Fig. 3D and Fig. S7C). In
high-grade lung tumors from siKras-treated mice, levels of pErk
were markedly lower compared with control tumors (Fig. 3 E
and F and Fig. S7D), suggesting that Kras knockdown inhibits
downstream MAPK signaling. Because low-grade KP tumors do
not stain positively for pErk (31), we were not able to measure
the pErk levels in low-grade tumors by immunohistochemistry.
To investigate mechanisms of tumor regression further, we
stained lung tumor sections with an antibody specific for CC3,
a marker of apoptosis. siKras-treated tumors had increased
numbers of apoptotic cells compared with tumors treated with
siLuc (Fig. 3 E and G). These data suggest that systemic siRNA
delivery reduced oncogenic Kras mRNA in vivo and that such
treatment led to antitumor responses. To confirm that these
effects were due to Kras inhibition rather than off-target effects,
we tested a second siRNA against Kras (siKras.1212). Once
again, we observed down-regulation of Kras expression in vitro
and antitumor effects in vivo (Fig. 3D and Figs. S7A and S8).
Concurrent Delivery of miR-34a and siKras Improves Therapeutic
Responses. RNAi-based therapeutics can potentially inhibit
multiple target genes and pathways via concurrent delivery of
distinct small RNAs. We hypothesized that targeting activated
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Kras by siRNA and stimulating p53-related responses with miR-
34a would increase antitumor activity in the KP mouse model.
Thus, we formulated 7C1 nanoparticles with the miR-34a mimic
and siKras in an equal molar ratio. Incubation of KP cells in vitro
with the miR-34a/siKras combination nanoparticles led to an
additive inhibition of cell proliferation compared with miR-34a
or siKras alone plus siLuc (Fig. 4A). To determine the thera-
peutic effects of combined miR-34a and siKras delivery in vivo,
KP mice in which tumors were initiated 10 wk earlier were
randomized into four nanoparticle treatment groups (n = 8 mice
per group): (i) siLuc, (ii) miR-34a/siLuc, (iii) siKras/siLuc, and
(iv) miR-34a/siKras. Mice were i.v. injected with a total small
RNA dose of 2.0 mg/kg every other day four times. In isolated
lung tumors, small RNA Q-PCR revealed increased miR-34a
levels and detectable siKras antisense-strand levels in miR-34a/
siKras combination-treated tumors (Fig. S9), demonstrating that
nanoparticles successfully delivered both small RNAs into lung
tumors. Moreover, microCT imaging revealed that miR-34a/
siKras combination therapy induced measurable lung tumor re-
gression, shrinking tumors to an average of 63% of the original
volume in 2 wk (Fig. 4B). Combination-treated tumors also
showed increased numbers of CC3-positive cells compared with
miR-34a or siKras alone (Fig. 4C). These data suggest that ef-
fective delivery of two therapeutic small RNAs is possible in
autochthonous lung tumors.
All animals tolerated small RNA therapy well, with only mild
weight loss observed after siKras or miR-34a/siKras combination
therapy (Fig. S6). Weight loss was not observed after injection of
nanoparticles formulated with siLuc or miR-34a mimic (Fig. S6),
suggesting that this effect was likely due to modulation of Kras
levels in normal tissue. To examine whether tumor regression
was due to a nonspecific immune response, we collected pe-
ripheral blood from animals treated with siLuc or miR-34a/
siKras nanoparticles 4 h and 24 h after the first injection and 4 h
after the fourth injection to monitor both acute and long-term
immune responses (48, 49) (Fig. S10A). The dosing regimen of
nanoparticles was identical to that used for tumor treatment
studies (Fig. 4B). As measured by ELISAs, levels of IL-6 and
IFN-α, indicators of nonspecific immune responses, were statis-
tically indistinguishable in PBS-, control siRNA-, or miR-34a/
siKras-treated animals at all time points (Fig. S10 B and C).
Histopathological analysis showed an absence of general tissue
toxicity after 7C1 miR-34a/siKras treatment (Fig. S10D). Col-
lectively, these data suggest that tumor regression was not caused
by an immunostimulatory effect of small RNA or nanoparticles.
Cisplatin is a first-line lung cancer chemotherapeutic agent
whose efficacy has been investigated in KP mice (25). To an-
alyze the long-term effects of nanoparticle therapy in combi-
nation with conventional chemotherapy and to examine its effect
on long-term survival, we investigated whether nanoparticles
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Fig. 4. Concurrent delivery of miR-34a and siKras combination improves therapeutic response. (A) KP cell number following incubation with 7C1-siRNA
combinations. Each siRNA dose is 30 nM. Error bars are SD (n = 3 wells per group). (B) Normalized lung tumor volume in KP mice following treatment with
7C1-siRNA combinations. Ten weeks after tumor initiation, mice were dosed with 2 mg/kg of 7C1-siLuc or 7C1–miR-34a/siKras every other day for four doses.
Error bars are SD (n = 8 mice per group, n = 1 tumor per mouse). **P < 0.01 for 7C1–miR-34a/siKras compared with single treatment. (C) Quantification of
apoptotic cells marked by CC3 in treated tumors (n = 27, 29, 36, and 46 tumors per time point, respectively). (D) Kaplan–Meier survival curve of KP mice
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to tumor initiation. Arrows or arrowheads indicate time points of cisplatin or nanoparticle administration, respectively. *P < 0.05; **P < 0.01.
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carrying miR-34a mimic and siKras could prolong life in mice
separately or in combination with cisplatin. We treated tumor-
bearing KP mice with either cisplatin, nanoparticles carrying
both miR-34a mimic and siKras, or a combination of the two.
Using the treatment regimen shown in Fig. 4D, KP mice treated
with both cisplatin and the nanoparticle formulated with a com-
bination of miR-34a/siKras (159.9 ± 19.5 d, n = 10 mice per
group; P < 0.01 compared with single treatment) survived sig-
nificantly longer than mice treated with siLuc (93.7 ± 16.1 d, n = 8
mice per group), cisplatin alone (127.4 ± 9.0 d, n = 8 mice per
group), or miR-34a/siKras alone (129.2 ± 16.2 d, n = 8 mice per
group). These data indicate that nanoparticle-mediated miR-
34a/siKras small RNA therapy can provide additional thera-
peutic effects in combination with conventional chemotherapeutic
strategies.
7C1 Carrying KRAS siRNA Has Therapeutic Effect in KRAS Mutant
Human NSCLC Cells. To assess whether 7C1 can deliver thera-
peutic siRNA to human NSCLC cells, we formulated 7C1
nanoparticles with siRNAs targeting human KRAS. The 7C1
carrying siKRAS led to marked knockdown of KRAS mRNA in
four human NSCLC cell lines harboring KRAS mutations and
resulted in a reduced cell number (Fig. S11 A and B). The 7C1
carrying siKRAS also reduced KRAS protein in H2009 cells
(Fig. S11C). To explore whether 7C1 formulated with siRNA
targeting human KRAS mRNA had therapeutic efficacy in vivo,
we injected KRAS mutant H2009 NSCLC cells s.c. into nude
mice and treated mice when tumors reached 100 mm3. Consis-
tent with our data in the autochthonous mouse model (Fig. 3),
7C1 formulated with siKRAS delayed tumor growth of H2009
xenograft (n = 6 tumors per group; Fig. S11D). These data in-
dicate that 7C1 nanoparticles are capable of delivering thera-
peutic siRNA in human NSCLC cells and xenograft tumors.
Discussion
Here, we have demonstrated that systemic delivery of a polymer-
based nanoparticle can deliver therapeutic small RNAs in an
autochthonous mouse model of lung cancer, and that targeted
combination RNA therapy can elicit a potent antitumor re-
sponse. Because a significant number of human lung tumors, as
well as other tumor types, carry mutations in KRAS and p53,
these results may have direct translational implications for hu-
man cancer treatment. Moreover, because 7C1 nanoparticles
complex the anionic RNA backbone independent of nucleotide
sequence, 7C1 can deliver therapeutic RNAs against additional
targets in tumor cells. This clearly demonstrates that combina-
tion small RNA therapy is a modular and flexible approach for
lung cancer treatment. Targeted multigene therapy may be used
for personalized therapies because combinations can be selected
against mutations identified in individual patients. As nano-
particle formulations targeted to different organs become
available, synthetic siRNA or miRNA can be formulated with
vehicles to target different organs of interest, potentially tar-
geting both primary and metastatic sites.
We show here that delivery of a miR-34a mimic modulated
miR-34 target genes in lung tumors and delayed tumor pro-
gression, suggesting that systematic delivery of miR-34 might be
a strategy to restore partial p53 downstream functions in TP53
mutant tumors (37). Delivery of miR-34a reduced cell pro-
liferation and delayed lung tumor growth, which is consistent
with a recent study in a KrasG12D;p53R172H lung cancer model
(12). Because miR-34 family miRNAs also inhibit key signaling
pathways, including NOTCH, WNT and MET (38), miR-34 may
play other tumor-suppressive functions in addition to cell cycle
regulation. To date, more than 30 genes targeted by miR-34a
have been reported in the literature (39). Because miRNAs
generally regulate large networks of target genes, miR-34a or
other tumor suppressor miRNAs could be used to inhibit tumor
cell proliferation and survival potently. Importantly, the in-
hibition of multiple target genes and pathways might limit the
ability of tumor cells to escape via secondary mutations. Future
work will address whether treated tumors acquire resistance
to small RNA therapies through mechanisms that include
reduced nanoparticle uptake, increased nanoparticle exo-
cytosis, and global down-regulation of RNAi pathway func-
tion, and whether combination therapies designed to inhibit
the expression of resistance-promoting genes simultaneously
can improve therapeutic efficacy.
Although small-molecule inhibition of oncogenic Kras has not
been successful to date (27), our results using Kras siRNA in-
dicate that RNAi may effectively reduce Kras activity in vivo and
induce antitumor effects (50). Because the siKras sequences in
this study target the 3′-UTR of Kras, both the G12D and the WT
Kras mRNA are suppressed by siKras. Future work is needed to
investigate how cells respond to the knockdown of WT Kras, and
whether mutant-specific forms of siKras can be developed.
Taking advantage of the ability to package multiple small
RNAs in a single nanoparticle formulation (51), we demon-
strated superior antitumor response with the combination of
miR-34a mimic and siKras in this model system. Molecular dis-
section of the interaction between the miR-34a and Kras net-
work will reveal how the miR-34a and siKras combination
improves therapeutic responses. When combined with cisplatin-
based chemotherapy, miR-34a/siKras delivery further extended
survival, indicating RNA therapy may be combined with che-
motherapy, radiation, or surgery to improve the efficacy of
existing cancer therapies. More specifically, the response to
chemotherapy might be improved by specifically modulating
genes in chemoresistance pathways. For example, murine lung
adenocarcinoma resistant to cisplatin treatment often has ele-
vated expression of the apoptosis modulator Pidd (25). Similarly,
MET tyrosine kinase amplification has been identified in some
EGFR inhibitor-resistant lung cancers (52).
Given that 7C1 nanoparticles are known to target endothelial
cells, additional studies are required to delineate the impact of
siKras and miR-34a delivery on normal tissue and the tumor
microenvironment. However, it is clear that these small RNAs
had direct effects on the tumor cells as well, as evidenced by
knockdown of a tumor cell-specific luciferase reporter in vivo
(Fig. 1E).
Taken together, our findings demonstrate the feasibility of
small RNA-based combination therapy in a physiologically rel-
evant mouse model of human lung cancer. The effective delivery
of small RNAs to solid tumors in the model, combined with the
modulation of divergent aspects of tumor biology as well as
potent therapeutic responses, provides a compelling case for the
use of small RNA therapies in human patients with lung cancer.
Materials and Methods
7C1 Nanoparticle Formulation. The 7C1 compound was synthesized and pu-
rified as previously described (45). Particles were formulated with a micro-
fluidic device (53) at a 7C1/RNA mass ratio equal to 5:1, dialyzed into 1× PBS,
filtered with a sterile 0.2-μm filter under a sterile biohood, and stored at 4 °C.
Particle diameter was measured with aMalvern Zetasizer (Malvern Instruments).
Mice and 7C1 Nanoparticle Treatment. All animal study protocols were ap-
proved by the Massachusetts Institute of Technology Animal Care and Use
Committee. Cohorts of KP and KP;R26LSL-Luciferase/LSL-tdTomato mice were
infected with 2.5 × 107 pfu of Adeno-Cre (University of Iowa) by intranasal
inhalation as described previously. Mice were injected with 7C1 nano-
particles i.v. and with cisplatin i.p. (25) as indicated. A total of 5 × 106 H2009
cells were injected s.c. in immunocompromised mice (6–8 wk old). Tumor
volume was measured by calipers and calculated as 0.52 × length × width2.
Upon tumor formation (∼100 mm3), mice were treated with PBS or 7C1
siRNA as indicated.
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Immunohistochemistry. Mice were killed by carbon dioxide asphyxiation.
Lungs were inflated with 4% formalin [neutral buffered formalin (vol/vol)],
fixed overnight, and transferred to 70% ethanol. Lung lobes were embed-
ded in paraffin, sectioned at 4 μm, and stained with H&E for tumor pa-
thology. Lung tumor sections were dewaxed, rehydrated, and stained using
standard immunohistochemistry protocols (22). The following antibodies
were used: anti-cleaved caspase 3 (1:200, catalog no. 9661; Cell Signaling),
anti-Ki67 (1:100, VP-K452; Vector Laboratory), anti-Phospho Histone H3
(1:200, catalog no. 9701; Cell Signaling), and anti-pErk Thr202/Tyr204 (1:300,
catalog no. 4370; Cell Signaling). The number of positive cells per tumor
area was quantified. Tumor numbers and mice numbers are indicated in
the figure legends.
MicroCT and Bioluminescence Imaging. At indicated time points, mice were
scanned for 5 min under isoflurane anesthesia using small animal micro-
computed tomography (eXplore CT120 whole-mouse microCT; GE Health-
care). Imageswere acquired and processed using GE eXplore software. One or
two independent lung tumors from each mouse were quantified. Bio-
luminescence imaging was performed as previously described (22). Signals in
mice or cells were quantified using Living Imaging software (Xenogen).
Immunoblotting, ELISA, and Immunofluorescence. Cell pellets were lysed in
Laemmli buffer. Equal amounts of protein (16 μg) were separated on 10%
SDS-polyacrylamide gels and transferred to PVDF membranes. Blots were
probed with antibodies (1:1,000 dilution) against Kras (sc-30), pErk (catalog
no. 4370; Cell Signaling), or tubulin. Serum cytokine concentrations were
measured in an ELISA-based assay according to the manufacturer’s instruc-
tions (eBiosciences). Immunofluorescence testing was performed as pre-
viously described (54). Goat antiluciferase (G7451; Promega) and donkey
anti-goat Alexa Fluor 488 (Invitrogen) antibodies were used. Slides were
counterstained with DAPI (Sigma) and mounted in Vectashield antifade
mountant (Vector Laboratories).
Cell Number Measurement. Cells were split into 96-well plates (1,000 cells per
well). After 24 h, cells were coincubatedwith 7C1 nanoparticles for 24 h. After
48–72 h, cell number was measure in triplicate using a CellTiter-Glo kit
(Promega). Control siRNA-treated cell values were set to 1 (100%). For Figs.
1D, 3A, and 4A and Fig. S11, the data are representative of two independent
experiments.
Gene Expression Analysis and Small RNA Q-PCR. RNA was purified using TRIzol
(Invitrogen) and reverse-transcribed using a High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Real-time PCR (Q-PCR) reactions were
performed using Taqman probes (Applied Biosystems). mRNA levels were
normalized to Actin mRNA. For measuring miRNA expression, 10 ng of total
RNA was reverse-transcribed using miRNA-specific RT primer and measured
by real-time PCR using miRNA-specific probes (Applied Biosystems). siKras
levels were quantified similarly using a customized small RNA Taqman assay
(Applied Biosystems). Data were normalized to the U6 RNA.
Sequence of Kras siRNAs (Antisense 5′–3′)
ON-TARGET plus Human KRAS SMART pool was purchased from Dhar-
macon. All siRNAs have dTdT overhang in the 3′-end.
Statistics. P values were determined by Prism 5 (GraphPad) and Student
t tests.
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